Compound Reference
Ipamorelin Research Overview
Last updated:
Ipamorelin is a synthetic pentapeptide studied as a growth-hormone secretagogue acting at the ghrelin (growth hormone secretagogue) receptor.
Ipamorelin has no approved human medical indication and has not been evaluated by the FDA or any other regulatory body for safety or efficacy in humans. Published research on Ipamorelin is overwhelmingly preclinical: conducted in vitro (cell and tissue culture) or in animal models, primarily rodents. We are not aware of well-controlled human clinical trials establishing a therapeutic effect for any condition.
Ipamorelin's preclinical literature is concentrated on receptor selectivity relative to other growth-hormone secretagogues:
- Growth-hormone secretagogue research — animal and pituitary-cell studies have examined ipamorelin's effect on growth-hormone release via ghrelin-receptor activation.
- Receptor-selectivity research — comparative studies have investigated ipamorelin's selectivity for growth-hormone release relative to other secretagogues studied for broader effects on cortisol and prolactin.
These are summaries of published research topics, not claims about what this product does, and animal-model findings do not establish an effect in humans. See References below to search the primary literature directly.
Limitations
State of the Evidence
Most published ipamorelin research addresses receptor selectivity in animal and cell-based systems; well-controlled human trials specific to ipamorelin itself are limited, and receptor-selectivity findings in vitro do not by themselves establish a clinical effect.
References
Primary Literature
The links below open a PubMed search for each research topic referenced above, rather than a single citation, so you can review the primary literature directly rather than rely on our summary of it.
All products are intended for laboratory and research purposes only. Not for human or veterinary use. Not a drug. Not for diagnostic or therapeutic use.